###### Strengths and limitations of this study

-   This is the first study that investigates the effectiveness and cost-effectiveness of duloxetine as a third-choice analgesic in primary care.

-   The efficacy of duloxetine has been demonstrated, but the effectiveness and cost-effectiveness are not yet known. The pragmatic open-label stratified cluster design of this trial is particularly appropriate to study the effectiveness of this treatment strategy in real-life clinical practice.

-   This is the first study that assesses if the effectiveness of duloxetine is predominantly found in those patients suffering from centrally sensitised pain.

-   The cluster randomised design can be prone to recruitment bias, though we aim to minimise this bias and maximise generalisability by identifying all eligible patients before randomisation.

-   Stratified randomisation for important GP practice characteristics is used to minimise the possible baseline imbalance between randomised groups.

Background and rationale {#s1}
========================

Osteoarthritis (OA) is a highly prevalent chronic condition of the musculoskeletal system. Approximately 15% of the population suffers from OA. Among elderly, the lifetime risk for knee OA is 40% in men and 47% in women[@R1] and it is the single-most contributing factor to a decreased physical well-being.[@R3] It is predicted that OA will become the fourth leading cause of disability worldwide by the year 2020.[@R4] The majority of patients suffering from OA are treated in primary care.[@R5] The general practitioner (GP) plays a key role in the treatment of symptomatic pain, the most debilitating symptom of this condition. Currently, usual care by the GP consists of education, referral for exercise therapy and prescribing symptomatic pain medication using a stepwise approach. The first step consists of paracetamol. If its analgesic effect proves insufficient, non-steroidal anti-inflammatory drugs (NSAIDs) can be prescribed as a second step, and subsequently tramadol or other opioids.[@R7] So far, however, the effectiveness of symptomatic pain treatment has proven to be limited[@R8] and the majority of the patients still report pain despite taking pain medication.[@R11] In addition, these analgesics are often contraindicated, especially in elderly patients, and they are associated with the occurrence of serious adverse reactions. Improved analgesic treatment or a new approach to OA pain treatment is therefore needed, especially since there are no treatment options available aimed at delaying or halting the process of OA. Surgical joint replacement is the exception but is an intervention which is costly, does not always lead to a satisfied results for patients and is also of limited durability.[@R4] An effective and relatively safe medicine, when current options fail, could improve the quality of life for these patients with chronic pain. In the long term, it could potentially help postpone the need for a joint replacement and revision surgery while retaining quality of life.

Traditionally, pain in OA was assumed to consist solely of nociceptive pain due to inflammation, degradation and remodelling of joint tissue. However, it has since been demonstrated that in addition to nociceptive pain, peripheral sensitised pain from locally generated inflammatory factors and centrally sensitised pain can be present in OA.[@R14] Intense, repeated or prolonged nociceptive input can lead to hyperexcitability of pain circuits in the central nervous system.[@R15] Normally, descending inhibitory pathways from the brainstem modulate pain processing through the release of norepinephrine and serotonin. These inhibitory pathways can be impaired in patients with OA.[@R15] This disinhibition of descending pathways further contributes to central sensitisation in OA. Centrally sensitised pain is present in a substantial percentage (30%--37%)[@R16] of patients with chronic pain due to OA and is thought to respond particularly poorly to currently prescribed analgesics, as it requires medication with a centrally acting agent. Duloxetine is a serotonin--norepinephrine reuptake inhibitor and acts centrally by strengthening the inhibition of the descending pathways.

Several randomised placebo-controlled trials have now demonstrated the efficacy of low-dose duloxetine versus placebo in the treatment of pain in OA (clinically relevant effect sizes of 0.4--0.5 for pain in OA[@R18] and 0.6 for disability in OA[@R18]) and the most recent guideline of the Osteoarthritis Research Society International (OARSI) now recommend duloxetine for the non-surgical management of knee OA.[@R10] These trials are short-term randomised placebo-controlled trials in a highly controlled and secondary care setting. The effectiveness of duloxetine as third-choice analgesia in general practice is not known. Neither is clear whether the effectiveness of duloxetine is predominantly found in those patients suffering from pain with characteristics of central sensitisation, or whether duloxetine as third-choice analgesia in general practice is cost-effective, if found effective.

Methods and design {#s2}
==================

Objectives {#s2a}
----------

The primary objective of this study is to investigate whether duloxetine added to usual care is effective as third-choice pain medication (when NSAIDs fail, are contraindicated or have intolerable side-effects) in reducing chronic pain Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in primary care patients with OA after 3 months, compared with usual care alone.

Secondary objectives are (1) to assess whether the presence of characteristics of central sensitisation (modified painDETECT \>12.0) favourably modifies the response to treatment with duloxetine (WOMAC pain at 3 months and WOMAC pain and function at 1 year) and (2) to examine the cost-effectiveness of treatment with duloxetine at 1 year.

Study design {#s2b}
------------

A pragmatic open-label cluster randomised controlled trial with a follow-up of 1 year is conducted ([figure 1](#F1){ref-type="fig"}). To avoid contamination between the two intervention groups, randomisation takes place on the level of the GP practice. Patients, researchers and GPs are not blinded to the assigned treatment.

![Flow chart of the study. GP, general practitioner; OA, osteoarthritis.](bmjopen-2017-018661f01){#F1}

Randomisation {#s2c}
-------------

GP practices are randomised to the duloxetine or usual care group. Since provided care can differ based on practice characteristics, stratification is performed on: (1) socioeconomic status of the practice location (low socioeconomic status vs normal and high socioeconomic status, based on the registration by the Netherlands Institute for Social Research[@R20]); (2) the number of GPs working at the practice (one full-time equivalent or smaller vs larger than one full-time equivalent) and (3) the mean age of the GPs per practice (younger than 50 years or 50 years and older).[@R21] The randomisation sequence is determined by an independent data manager from the department, with the use of a computer-generated randomisation list. A block design with blocks random varying between two and six is used to equally balance the groups. The randomisation procedure is concealed to the involved researchers of the study. Randomisation of the GP practice is performed after eligible patients are identified and the first patient of the GP practice has signed informed consent.

Inclusion criteria {#s2d}
------------------

All patients must be aged 18 years or older and have hip and/or knee OA based on the clinical American College of Rheumatology criteria.[@R24] Chronic pain should be present, which is defined as pain on most days during the last 3 months. In addition, patients must have insufficient benefit of NSAIDs, contraindications for NSAIDs or previous adverse reactions to NSAIDs (ie, eligible for third-choice pain medication).

Exclusion criteria {#s2e}
------------------

Patients who meet one of the following criteria will be excluded from the trial.Scheduled for a hip or knee replacement;Current use of antidepressants;Current use of neuropathic pain medication;Rheumatoid arthritis;Unable to sign informed consent;Contraindications for duloxetine (current use of monoamine oxidase inhibitors, uncontrolled narrow-angle glaucoma, the combination with other central nervous acting drugs (eg, benzodiazepines), hypersensitivity to duloxetine, liver disease resulting in hepatic impairment, severe renal impairment (creatinine clearance \<30 mL/min), current use of strong CYP1A2 inhibitors, current use of CYP2D6 inhibitors and substrates, uncontrolled hypertension, pregnancy or lactation).

Initially, patients who currently used opioids or used these in the past 3 months were excluded from the trial, because opioids are already third-choice medication in the Netherlands. Though, when patients still feel pain despite the use of opioids, it may be that these complaints reflect a centrally sensitised pain, since this type of pain is thought to respond less well to traditional analgesics. Especially these patients can benefit from duloxetine. Therefore, these patients are also eligible.

Intervention {#s2f}
------------

### Duloxetine {#s2f1}

Patients in the duloxetine arm are prescribed duloxetine 60 mg once a day. During the first week of treatment, the patient starts with 30 mg duloxetine per day to minimise potential adverse events due to duloxetine. If tolerated well, the dose is increased to 60 mg/day in the second week. Therapeutic benefit of duloxetine is assessed regularly by the treating GP (after 2 weeks, 1, 3, 6, 9, 12 months and when necessary). If patients experience no effect of duloxetine after 3 months or patients experience intolerable side effects, duloxetine can gradually be discontinued. Patients also receive usual care according to the GP guidelines in the Netherlands,[@R7] as described below.

### Usual care {#s2f2}

Patients are treated according to the current Dutch GP guideline which comprise education, life style advice, dietary therapy, physiotherapy and analgesics.[@R7] Analgesics are prescribed according to the opinion and experience of the treating GP. Analgesic choice depends on what the GP and patients decide. Paracetamol and NSAIDs have failed in these patients. A GP can decide to prescribe or continue an opioid, or the treatment can remain the same. Depending on the comorbidities of the patients, contraindications and opinion of the GP other interventions are also allowed.

### Cointerventions {#s2f3}

Patients assigned to the usual care group cannot be prescribed duloxetine. In both groups, intra-articular injection with glucocorticoids or a referral for joint replacement is allowed, as these are in accordance with Dutch GP guidelines and appropriate within the pragmatic design of this trial.

Study procedures {#s2g}
----------------

Patients are recruited from general practices. GPs in the Rotterdam region are invited to participate. If a GP practice is held by more than one GP, all GPs are randomised into the same arm. In this way, contamination between the groups is prevented when a patient visits another GP in the same practice. Demographic characteristics of the GP practice are registered. Randomisation of the GP practice is performed after the first patient of the GP practice has signed the informed consent form.

All eligible patients are identified by an electronic search in the participating GPs medical records. The GP decides which patients receive an invitation for the trial. In this way, possible recruitment bias can be monitored. Subsequently, eligible patients are sent information about the current trial. If a patient is interested in participating, the patient is contacted by a member of the research team over telephone. During this contact, the study is explained and eligibility of the patient is re-evaluated. If a patient is interested and eligible, the patient receives further written information about the study. After 2 weeks, the patients is contacted a second time over telephone to obtain informed consent. After filling out the baseline questionnaire, patients are told to which intervention their GP practice is randomised. In both study arms, patients consult their GP for their intervention ([figure 1](#F1){ref-type="fig"}). In the duloxetine arm, the GP prescribes duloxetine during the consultation. If at this point the patient decides not to take the duloxetine after all, the patient remains in the study in accordance with the pragmatic approach.

Patients receive follow-up questionnaires at 6 weeks, 3, 6, 9 and 12 months ([table 1](#T1){ref-type="table"}) after filling out the baseline questionnaire. The questionnaire at 6 weeks is added to the initial protocol to monitor the therapeutic effect of duloxetine more closely in the first weeks.

###### 

Overview of questionnaire items

                                                                 Baseline   6 weeks   3 months   6 months   9 months   12 months
  -------------------------------------------------------------- ---------- --------- ---------- ---------- ---------- -----------
  Outcome measures                                                                                                     
   Pain score (WOMAC)                                            X          X         X          X          X          X
   Function score (WOMAC)                                        X          X         X          X          X          X
   HOOS/KOOS                                                     X          X         X          X          X          X
   Quality of life (EuroQol-5D-5L)                               X                    X          X          X          X
   Medical costs (iMCQ)                                          X                    X          X          X          X
   Productivity cost (iPCQ)                                      X                    X          X          X          X
   Cointerventions                                                          X         X          X          X          X
   Adverse events                                                           X         X          X          X          X
   Compliance                                                    X                    X          X          X          X
   Patients satisfaction                                                    X         X          X          X          X
  Others                                                                                                               
   Demographic data                                              X                                                     
   Comorbidities                                                 X                                                     
   Presence of centrally sensitised pain (modified painDETECT)   X                                                     
   Presence of depression or anxiety (HADS)                      X                    X          X          X          X

HADS, Hospital and Anxiety Depression Scale; HOOS, Hip disability and Osteoarthritis Outcome Score; iMCQ, iMTA Medical Cost Questionnaire; iPCQ, iMTA Productivity Cost Questionnaire; KOOS, Knee Injury and Osteoarthritis Outcome Score; WOMAC, Western Ontario and McMaster University Osteoarthritis Index.

Safety {#s2h}
------

All adverse events reported by the subject are recorded. All serious adverse events (SAEs) are reported to the medical ethics committee (MEC). All SAEs are monitored until resolution or stabilisation. No Data and Safety Monitoring Board is needed, since adverse events of duloxetine are well known and duloxetine is registered in the Netherlands for the treatment of depressive disorders and diabetic neuropathy. Monitoring of the study is carried out once a year because of the negligible risk profile (Standards of The Netherlands Federation of University Medical Centres).[@R25]

Outcome measures {#s2i}
----------------

### Primary outcome {#s2i1}

The primary outcome is pain at 3-month follow-up measured with the WOMAC pain subscale. During the study period, patients complete the Knee Injury and Osteoarthritis Outcome Score (KOOS) or the Hip Disability and Osteoarthritis Outcome Score (HOOS).[@R26] The HOOS and KOOS consist of five subscales: pain, other symptoms, ADL function, function in sport and recreation, and knee/hip-related quality of life. The KOOS and HOOS are developed as an extension of the WOMAC score, with the purpose of evaluating both short-term and long-term symptoms and function. All WOMAC pain and function questions are included in their full and original forms in the KOOS/HOOS questionnaire.[@R26] Therefore, WOMAC scores can be calculated from the KOOS and HOOS scores. The questions apply to the previous week and each indicator is scored on a 5-point Likert scale (0=extreme problems and 4=no problems). Scores range between 0 and 100, and higher scores indicate less symptoms.

### Secondary outcomes {#s2i2}

Secondary outcomes are pain at 1 year (WOMAC pain subscale) and disability at 1 year (WOMAC function subscale). Adverse reactions and cointerventions for OA pain are systematically recorded in the follow-up questionnaires. Patients' satisfaction with the treatment is measured on an 11-point numerical rating scale (0=completely dissatisfied, 10=completely satisfied).

Health-related quality of life is measured with the EuroQol-5D (EQ-5D-5L) which comprises a descriptive system with five dimensions and a Visual Analogue Scale.[@R29] Costs are measured using the iMTA Medical Consumption Questionnaire (iMCQ) and the iMTA Productivity Cost Questionnaire (iPCQ). The iMCQ is a non-disease-specific questionnaire to determine the direct medical and patients' costs of the previous 3 months.[@R30] The iPCQ is focused on the indirect costs of the healthcare system; it measures the productivity losses in the last 4 weeks.[@R31]

Compliance to the treatment is estimated by questions about medication use (dose, how often each day, number of days). Furthermore, the Beliefs about Medication Questionnaire (BMQ) is asked. The BMQ consists of two sections: the BMQ-General and BMQ-Specific section[@R32] assessing patients' thoughts about medicine in general and about OA medication specifically. Each section consists of two subscales. The BMQ-General contains the subscales Harm and Overuse (scores 4--20). The BMQ-Specific encompasses the subscales Necessity and Concerns (scores 5--25). Higher scores on the BMQ-Specific section are correlated with self-reported therapy adherence.[@R33]

The effect of the intervention will also be evaluated by the OMERACT-OARSI response criteria. These criteria are a uniform core set of outcome measurements for OA. Response is defined as (1) a high improvement in pain (WOMAC pain) or function (WOMAC function) (≥50%) and an absolute change of ≥20 (on an interval scale 0--100) or (2) improvement in at least two of the three following: pain ≥20% (WOMAC pain) and absolute change ≥10; function ≥20% (WOMAC function) and absolute change ≥10; patients' global assessment ≥20% and absolute change ≥10.[@R35]

### Other study outcomes {#s2i3}

At baseline the following patient characteristics are collected: age, gender, height and weight, education, comorbidities and the duration of complaints. In addition, patients fill out the modified painDETECT questionnaire which is adapted for patients with OA.[@R36] This questionnaire is validated for identifying 'neuropathic-like' symptoms which correlate with signs of central sensitisation in OA. Higher modified painDETECT scores indicate the presence of central sensitisation (scores\>12, range −1 to 35).[@R16] The modified painDETECT was recently validated in Dutch for both patients with knee OA and for patients with hip OA.[@R38]

Finally, the Hospital Anxiety and Depression Scale is assessed to establish the analgesic effect of duloxetine independent of the effects on mood or anxiety.[@R39]

Sample size {#s2j}
-----------

To detect a clinically relevant difference in WOMAC pain of 1.9 points (pooled SD 4.8)[@R18] between the two treatment groups with an effect size of 0.4 (power 80%; alpha 0.05), taking into account the cluster randomisation with an assumption of three patients per GP and an intracluster correlation coefficient (ICC) of 0.01, 102 patients per treatment group are required. As we expect around 10% loss to follow-up,[@R40] we need to include 224 in total (2×112). In order to detect an effect (with an effect size of 0.6) in the patients with centrally sensitised pain we need 44 patients per group (with the same power and cluster assumptions). In the patients who are currently included in the trial, centrally sensitised pain (PainDETECT score \>12) is present in 47% of the included patients. This percentage is higher than in the general OA population (37%).[@R16] This over-representation is probably related to our inclusion and exclusion criteria. When we assume a presence of centrally sensitised pain in 47% of our included patients, 206 patients need to be included to answer the secondary objective. Therefore, no sample size adjustments have to be made.

The current sample size is adjusted due to recruitment problems. In the initial sample size calculation, 362 patients needed to be included to detect a clinically relevant difference in WOMAC pain of 1.9 points. In this calculation, an ICC of 0.1 and five patients per GP were assumed. The inclusion of five patients per GP was not feasible and therefore this number was altered to three. Furthermore, the ICC of 0.1 was a conservative estimate and an ICC tends to be around 0.01 in general practice.[@R41]

Data management {#s2k}
---------------

All personal data are handled confidentially and anonymously. Each patient is allocated a unique code, which is used on the questionnaires and in the database. The link between the code and the patient identification is only be accessible to the researcher and the data manager. The software programs LimeSurvey and GemsTracker are used for the online questionnaires and patients' personal data, respectively.

Patient involvement {#s2l}
-------------------

Within the department of General Practice a patient panel exists (Primeur Patient Panel), with patient representatives who are involved in all phases of research.[@R42] Patient representatives from the Primeur Patient Panel, familiar with OA, have helped to design this study and will be involved in all phases of the study. They read and gave comments on the proposal, all patient information and procedures.

Statistical analysis {#s2m}
--------------------

Descriptive statistics will be used to describe patient characteristics, baseline values of the outcome measures and compliance to the intervention. Primary (WOMAC pain at 3 months) and secondary (WOMAC pain and function at 1 year) outcomes will be analysed using generalised linear mixed models with repeated measurements. The stratified cluster randomisation will be taken into account when analysing the data (multilevel analysis). When baseline characteristics are statistical significantly different between the two treatment groups, we will perform a confounder analysis. If the effect on the outcome changes 10% or more the baseline characteristic will be considered a confounder and analyses will be adjusted accordingly. All analyses will be performed following the intention-to-treat principle. Additional per protocol analyses will also be carried out; for the primary outcome, WOMAC pain at 3 months, in the intervention arm patients who discontinued duloxetine (within 4 weeks after start) or did not start at all will not be considered, and patients in the control arm who were prescribed antidepressants will not be considered. Subgroup analyses to assess the effectiveness of treatment in patients with centrally sensitised pain will be completed in patients who score higher than 12 on the modified painDETECT. The same analysis as described earlier will be carried out.

To evaluate cost-effectiveness of usual care and duloxetine versus usual care only in patients with chronic pain due to hip or knee OA, a cost-effectiveness analysis will be performed using the primary outcome: pain measured with the WOMAC questionnaire. A cost--utility analysis will be performed to compare our study with other studies in OA research using a general accepted outcome: quality-adjusted life years (QALYs). To calculate QALYs based on the EQ-5D-5L, utility values of the Dutch public for EuroQol health states will be applied.[@R43] Using non-parametric bootstrapping (randomly drawing 2500 observations with replacement from the patient sample), the degree of uncertainty for costs and health effects and the cost--utility ratio will be depicted in a cost-effectiveness plane.

In addition, an acceptability curve is drawn, which indicates the probability that the intervention has lower incremental cost per QALY gained than various thresholds for the maximum willingness to pay for an extra QALY.

Social perspective and healthcare perspective will be the basis of the economic analysis in which the direct and productivity costs in the groups will be compared using the iMCQ[@R30] and the Productivity Cost Questionnaire.[@R31]

Spirit guidelines {#s2n}
-----------------

This protocol meets the SPIRIT guidelines for reporting on study protocols for clinical trials.

Dissemination {#s3}
=============

Results will be communicated at international and national conferences and will be published in a scientific peer-reviewed journal. Together with the patient representatives of the Primeur Patient Panel, the results and ideas for dissemination will be discussed. They will check the validity of the conclusions from a public perspective and highlight findings that are more relevant to the public.

Substantial protocol amendments will be communicated to the MEC, the competent authority (Centrale Commissie Mensgebonden Onderzoek), ZonMw and cooperating GPs.

Discussion {#s4}
==========

This study assesses the effectiveness and cost-effectiveness of duloxetine added to usual care for patients with chronic pain due to hip and/or knee OA in a primary care setting. As far as we know this is the first pragmatic trial in which duloxetine is compared directly with usual care in primary care to establish the effectiveness of treatment with duloxetine. Until now only the efficacy has been shown.[@R18] Long-term effects, the comparison with usual care and cost-effectiveness are unknown.

This pragmatic trial evaluates the use of duloxetine in everyday practice and has a high external validity due to the relatively unselected patients and flexible conditions. Therefore, the DUO trial will be helpful in answering the question whether the interventions has additional value in 'real life'.[@R46]

We choose the cluster randomised design, because the design has particular utility in effectiveness and implementation studies. This design is particularly appropriate for the evaluation of interventions that naturally are applied at cluster level, for example, general practices that choose a certain stepped approach.[@R47]

Issues that require specific attention in this trial due to the cluster design are the generalisability, recruitment bias and possible baseline imbalances between the randomised groups. We monitored the risk of recruitment bias and maximised the generalisability by inviting all eligible patients from a cluster to participate in this study. Possible baseline imbalances are minimised by the stratification of the clusters.

Finally, it is not known whether the presence of centrally sensitised pain favourably modifies the treatment response to duloxetine. The modified painDETECT is a questionnaire that can be easily used in a primary care setting, in contrast to traditional extensive measurements such as quantitative sensory testing.[@R16] Patients with knee OA with higher modified painDETECT scores (\>12) have higher odds of having signs of central sensitisation.[@R16] If the presence of centrally sensitised pain does modify treatment response to duloxetine, this finding will enable more targeted treatment choices in primary care patients with OA.

In conclusion, the DUO trial is a cluster randomised trial to assess the effectiveness of duloxetine in patients with hip or knee OA with chronic pain in primary care. The trial will answer the question whether duloxetine can be used as third-choice pain medication in primary care and may enable more targeted treatment choices.
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